William Blair Initiates Coverage on CDNA with Market Perform Rating

CareDx (CDNA) has been initiated with a "Market Perform" rating by William Blair analyst Andrew Brackmann. The initiation marks a new coverage by the investment bank, which currently has no price target specified for the stock. CareDx operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The average target price for CDNA is $22.50, with a high estimate of $28.00 and a low estimate of $14.00, indicating an upside of 76.47% from the current price of $12.75.

William Blair analyst Andrew Brackmann has initiated coverage on CareDx, Inc. (CDNA), assigning the stock a "Market Perform" rating. This marks the investment bank's entry into the company's coverage, with no price target specified for the stock at this time. CareDx operates as a precision medicine company specializing in the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

CareDx offers a range of diagnostic services, including testing solutions like AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. These services are designed to support the pre- and post-transplant patient journey, utilizing genomics-based information to improve transplant outcomes.

The average target price for CDNA is $22.50, with estimates ranging from $14.00 to $28.00. This indicates an upside potential of 76.47% from the current price of $12.75. The company's revenue is expected to reach $367 million in 2025 and $407 million in 2026, driven by a growing market and government initiatives like the IOTA model.

William Blair's analysis highlights CareDx's strong position within the transplant ecosystem, which is dominated by 250 cardiothoracic and abdominal transplant centers, and a total addressable market (TAM) of $8 billion. The company's expanding portfolio of offerings, growing transplant cases, and leading share in testing services are expected to contribute to sticky, predictable, and profitable revenue growth.

References:
[1] https://www.williamblair.com/News/CareDx-Inc-Initiation
[2] https://www.marketscreener.com/news/william-blair-initiates-coverage-on-caredx-with-market-perform-rating-ce7c50d9d88df324